The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 435 participants.
Also called NCT01618162
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 435 participants
- Sponsor
- Registry
-
NCT01618162 -
2012-000140-97
-
- Other papers using this trial's data
- Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Germany, India, Israel, Puerto Rico, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01618162. Randomized; double masking; primary purpose treatment. Start 2012-08-29 (actual); primary completion 2013-10-23 (actual). Results posted on 2017-02-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
- Acronym
- DUAL™IV
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01618162- Content hash
604c795de2e3d9be73152ab6b8e8260d57fdb8b4af26af116276729856fed7ac